arrow_back Back to App

Streamlining Approval for Generic Animal Drugs

This act aims to simplify the approval process for generic animal drugs. This could lead to more affordable generic drug options becoming available, potentially lowering veterinary care costs for animal owners. These changes may impact the availability and pricing of medications for pets and livestock.
Key points
Simplifies bioequivalence study requirements for generic animal drugs, potentially speeding up their market entry.
Defines bioequivalence for animal drugs to require demonstration in at least one major species for which the drug is approved.
May lead to lower animal treatment costs due to increased competition and availability of cheaper alternatives.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_8857
Sponsor: Rep. Mace, Nancy [R-SC-1]
Process start date: 2022-09-15
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Generic Animal Drug Advancement Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_8857.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-09-15.

What are the main provisions?

Key points include:

  • Simplifies bioequivalence study requirements for generic animal drugs, potentially speeding up their market entry.
  • Defines bioequivalence for animal drugs to require demonstration in at least one major species for which the drug is approved.
  • May lead to lower animal treatment costs due to increased competition and availability of cheaper alternatives.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Mace, Nancy [R-SC-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Agriculture